Cagrilintide
Cagrilintide (NN9838)
Long-acting amylin analog powering CagriSema
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk for obesity and type 2 diabetes. It is a key component of CagriSema, the combination therapy with semaglutide.
Admin routes
Subcutaneous
Popularity
Medium
Side effects
Generally mild
AU vendors
0 rated
✓Key benefits
📈What to expect
Appetite suppression and early weight loss during dose escalation
Significant weight loss trajectory established
Approximately 25% total body weight loss (CagriSema trial average)
Based on community reports and published research. Individual results vary significantly.
💊Dosing protocols
CagriSema (combination therapy)
2.4 mg cagrilintide + 2.4 mg semaglutide
Once weekly (subcutaneous)
Ongoing treatment
Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.
Research status|Phase 3 trials complete, FDA filing underway for CagriSema
Overview
Cagrilintide mimics the hormone amylin, which is co-secreted with insulin by pancreatic beta cells after meals. Amylin slows gastric emptying, promotes satiety, and suppresses glucagon secretion. Natural amylin has a half-life of minutes; cagrilintide is engineered for weekly dosing. The real excitement is CagriSema, a fixed-ratio combination of cagrilintide with semaglutide (2.4 mg). Phase 3 REDEFINE trials showed CagriSema achieving approximately 25% body weight loss, exceeding either drug alone and approaching what was previously only achievable with bariatric surgery.
⚙️How it works
Cagrilintide is an acylated amylin analog that binds to amylin receptors (calcitonin receptor complexed with RAMP1, RAMP2, or RAMP3). It slows gastric emptying, increases satiety signals to the brain, inhibits glucagon secretion, and reduces food intake. When combined with semaglutide (a GLP-1 agonist), the two mechanisms work through complementary appetite and metabolic pathways, producing greater weight loss than either alone.
⚡Side effects
📅Research history
Phase 2 data for cagrilintide monotherapy published
CagriSema Phase 3 REDEFINE 1 results show ~25% weight loss
FDA filing for CagriSema submitted by Novo Nordisk
CagriSema vs semaglutide alone
The REDEFINE 1 trial compared CagriSema against semaglutide 2.4 mg alone and placebo. At 68 weeks, CagriSema produced approximately 25% weight loss versus 16% for semaglutide alone. This difference is clinically meaningful since it brings pharmacological weight loss closer to bariatric surgery outcomes (typically 25-35%). The combination works because amylin and GLP-1 regulate appetite through different brain circuits.
References
- [1]Frias JP, et al. 'Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes.' Lancet, 2023.
- [2]Novo Nordisk REDEFINE clinical trial program results, 2024.
Frequently asked questions
Related peptides
Semaglutide
Weight ManagementThe GLP-1 agonist behind the weight loss revolution
5 rated vendors
Tirzepatide
Weight ManagementThe dual-action GLP-1 that outperforms Ozempic in every trial
2 rated vendors
Liraglutide
Weight ManagementThe original daily GLP-1 agonist for weight and metabolic health
0 rated vendors
Retatrutide
Weight ManagementThe triple agonist showing 24% weight loss in trials
1 rated vendors
GLP-1
Weight ManagementThe natural hormone behind the weight loss revolution
0 rated vendors
Community experiences
Share your experience with Cagrilintide. Effects, side effects, protocol details - help others make informed decisions.
No community reviews yet. Be the first to share your experience with Cagrilintide.
Need to calculate your dose?
Use our free reconstitution calculator to work out syringe units for Cagrilintide.
Open CalculatorFound this useful?
Share this guide
Disclaimer: This guide is for educational and informational purposes only. It is not medical advice. The dosing protocols listed are sourced from published research and community reports and do not constitute a recommendation. Always consult a qualified healthcare professional before using any peptide. Australian regulations classify many peptides as Schedule 4 (prescription-only) substances. Check current TGA guidelines before purchasing.